Registry-listed formulations

Osanetant · chembl:CHEMBL346178

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • ACER-801 50 mg BIDRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ACER-801 100 mg BIDRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ACER-801 200 mg BIDRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Early Phase 1
2
67%
Phase 1/2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1/2Combined phases
1(33.3%)

Highest Phase Reached

Phase 1/2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Completed1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (66.7%)
Phase 1/21 (33.3%)

Trials by Status

completed133%
terminated133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1_2

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

NCT05325775
terminatedearly_phase_1

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

NCT05607342
withdrawnearly_phase_1

Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate

NCT05647447

Clinical Trials (3)

Showing 3 of 3 trials
NCT05325775Phase 1/2

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Completed
NCT05607342Early Phase 1

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

Terminated
NCT05647447Early Phase 1

Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
3

External References

ChEMBL
CHEMBL346178

Names & Codes

Research Codes

SB-236984SR-14280SR-142801